Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer.

Liu G, Oettel K, Bailey H, Ummersen LV, Tutsch K, Staab MJ, Horvath D, Alberti D, Arzoomanian R, Rezazadeh H, McGovern J, Robinson E, DeMets D, Wilding G.

Invest New Drugs. 2003 Aug;21(3):367-72.

PMID:
14578686
2.

Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer.

Bailey HH, Attia S, Love RR, Fass T, Chappell R, Tutsch K, Harris L, Jumonville A, Hansen R, Shapiro GR, Stewart JA.

Cancer Chemother Pharmacol. 2008 Jun;62(1):149-57. Epub 2007 Sep 21.

PMID:
17885756
3.

A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96.

Bailey HH, Levy D, Harris LS, Schink JC, Foss F, Beatty P, Wadler S.

Gynecol Oncol. 2002 Jun;85(3):464-8.

PMID:
12051875
4.

Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer.

Meadows SM, Mulkerin D, Berlin J, Bailey H, Kolesar J, Warren D, Thomas JP.

Int J Gastrointest Cancer. 2002;32(2-3):125-8.

PMID:
12794248
5.

A phase I trial of perillyl alcohol in patients with advanced solid tumors.

Azzoli CG, Miller VA, Ng KK, Krug LM, Spriggs DR, Tong WP, Riedel ER, Kris MG.

Cancer Chemother Pharmacol. 2003 Jun;51(6):493-8. Epub 2003 Apr 15.

PMID:
12695855
6.

A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.

Bailey HH, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Marnocha R, Holstein SA, Stewart J, Lewis KA, Hohl RJ.

Cancer Chemother Pharmacol. 2004 Oct;54(4):368-76. Epub 2004 Jun 15.

PMID:
15205914
7.

A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer.

Liu G, Gandara DR, Lara PN Jr, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G.

Clin Cancer Res. 2004 Feb 1;10(3):924-8.

8.

Phase I trial of perillyl alcohol administered four times daily continuously.

Morgan-Meadows S, Dubey S, Gould M, Tutsch K, Marnocha R, Arzoomanin R, Alberti D, Binger K, Feierabend C, Volkman J, Ellingen S, Black S, Pomplun M, Wilding G, Bailey H.

Cancer Chemother Pharmacol. 2003 Nov;52(5):361-6. Epub 2003 Aug 2.

PMID:
12904896
9.
10.

Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.

Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Binger K, Tutsch KD, Pomplun M, Wahamaki A, Marnocha R, Wilding G, Bailey HH.

Clin Cancer Res. 2000 Feb;6(2):390-6.

11.

A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group.

Moore MM, Stockler M, Lim R, Mok TS, Millward M, Boyer MJ.

Cancer Chemother Pharmacol. 2010 Oct;66(5):845-50. doi: 10.1007/s00280-009-1228-x. Epub 2010 Jan 16.

PMID:
20082080
12.

Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.

Hainsworth JD, Meluch AA, Spigel DR, Barton J Jr, Simons L, Meng C, Gould B, Greco FA.

Clin Genitourin Cancer. 2007 Mar;5(4):278-83.

PMID:
17553208
13.

Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.

Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ.

J Urol. 2002 Aug;168(2):542-5.

PMID:
12131305
14.

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).

Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G.

Invest New Drugs. 2011 Dec;29(6):1465-74. doi: 10.1007/s10637-010-9455-x. Epub 2010 May 25.

15.

Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.

Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM, Langer CJ, Litwin S, Yeslow G, Halberr T, Qian M, Gallo JM.

Clin Cancer Res. 2000 Aug;6(8):3071-80.

16.

Phase II study of topotecan in metastatic hormone-refractory prostate cancer.

Hudes GR, Kosierowski R, Greenberg R, Ramsey HE, Fox SC, Ozols RF, McAleer CA, Giantonio BJ.

Invest New Drugs. 1995;13(3):235-40.

PMID:
8729952
17.

A phase II clinical trial of sorafenib in androgen-independent prostate cancer.

Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz J, Jones E, Chen CC, Figg WD.

Clin Cancer Res. 2008 Jan 1;14(1):209-14. doi: 10.1158/1078-0432.CCR-07-1355.

18.
19.

Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.

Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L.

J Clin Oncol. 2005 Jan 20;23(3):455-60.

PMID:
15659491
20.

Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).

Kattan JG, Farhat FS, Chahine GY, Nasr FL, Moukadem WT, Younes FC, Yazbeck NJ, Ghosn MG; Cancer Research Group..

Invest New Drugs. 2008 Feb;26(1):75-9. Epub 2007 Sep 6.

PMID:
17846704

Supplemental Content

Support Center